AI Article Synopsis
- The study investigates a new urine test, Uromonitor-V2, for detecting non-muscle-invasive bladder cancer (NMIBC) recurrence, aiming to reduce reliance on traditional cystoscopy and urine cytology.
- The research involved 105 patients, with 97 eligible, revealing that Uromonitor-V2 had significantly higher sensitivity (93.1%) and negative predictive value (95.3%) than urine cytology.
- The findings suggest Uromonitor-V2 could be a more effective method for monitoring NMIBC recurrence, notably due to its strong negative predictive performance.
Article Abstract
The costly and burdensome nature of the current follow-up methods in non-muscle-invasive bladder cancer (NMIBC) drives the development of new methods that may alternate with regular cystoscopy and urine cytology. The Uromonitor-V2 is a new urine-based assay in the detection of hotspot mutations in three genes (, , and ) for evaluation of disease recurrence. The aim of this study was to investigate the Uromonitor-V2's performance in detecting NMIBC recurrence and compare it with urine cytology. From February 2018 to September 2019 patients were enrolled. All subjects underwent a standard-of-care (SOC) cystoscopy, either as part of their follow-up for NMIBC or for a nonmalignant urological pathology. Urine cytology was performed in NMIBC patients. Out of the 105 patients enrolled, 97 were eligible for the study. Twenty patients presented nonmalignant lesions, 29 had a history of NMIBC with disease recurrence, and 49 had a history of NMIBC without recurrence. In NMIBC, the Uromonitor-V2 displayed a sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 93.1%, 85.4%, 79.4%, and 95.3%, respectively. Urine cytology was available for 52 patients, and the sensitivity, specificity, PPV, and NPV were 26.3%, 90.9%, 62.5%, and 68.2%, respectively. With its high NPV of 95.3%, the Uromonitor-V2 revealed promising properties for the follow-up of patients with NMIBC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599569 | PMC |
| http://dx.doi.org/10.3390/diagnostics10100745 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Membranoproliferative glomerulonephritis (MPGN) has previously been used as an umbrella term to describe a spectrum of hypocomplementemic glomerular diseases, which are rare causes of end stage kidney disease (ESKD). We present a 22-year-old man with a well-established medical history who had been complaining of 4 days of frothy dark urine, bilateral lower limb swelling, and puffiness on his face. For a month before his presentation, he had many bilateral skin lesions on his lower limbs that were leaking pus.
View Article and Find Full Text PDFCausal genes identification of giant cell arteritis in CD4+ Memory t cells: an integration of multi-omics and expression quantitative trait locus analysis.
Inflamm Res
January 2025
Queen's Belfast University, Belfast, Northern Ireland, UK.
Background: Giant cell arteritis (GCA) is a prevalent artery and is strongly correlated with age. The role of CD4+ Memory T cells in giant cell arteritis has not been elucidated.
Method: Through single-cell analysis, we focused on the CD4+ Memory T cells in giant cell arteritis.
Introduction: The use of urine cytobacteriological examination is a common and essential practice in medicine which helps guide therapeutic management in case of urinary tract infection. The cytological examination of urine samples can be done using the manual (microscopic) or automated technique. The automated approach, which involves the use of artificial intelligence, is faster, more reliable, and more efficient for laboratories.
View Article and Find Full Text PDFMatched serum- and urine-derived biomarkers of interstitial cystitis/bladder pain syndrome.
PLoS One
December 2024
Institute of Cell Biology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Setting up the correct diagnosis of interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder, is a challenge, as there are neither diagnostic criteria nor reliable and non-invasive disease biomarkers available. The aim of the present study was to simultaneously determine matched serum- and urine-derived biomarkers of IC/BPS, which would provide additional insights into disease mechanisms and set the basis for further biomarker validation. Our study included 12 female patients with IC/BPS and 12 healthy controls.
View Article and Find Full Text PDFIdentifying optimal candidates for active surveillance in low-grade intermediate-risk non-muscle invasive bladder cancer.
World J Urol
December 2024
Division of Experimental Oncology, Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Via Olgettina, 60, 20132, Milan, Italy.
Objective: The intermediate-risk non-muscle invasive bladder cancer (IR-NMIBC) prognostic group is heterogeneous. Growing evidence supports the role of active surveillance (AS) for patients with low-risk NMIBC, however, no clear data exists considering IR-NMIBC. The aim of the study was to assess the risk of recurrence of patients eligible for AS based on the International Bladder Cancer Group (IBCG) stratification.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!